Beibei Guo

MathematicsImmunology and MicrobiologyDecision SciencesEngineeringChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients”.

Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients

Cost Effectiveness and Resource Allocation(2020)10.1186/s12962-020-00222-y

N/A

0DataRank · unranked

11 citations

Beibei Guo, Rui Zhang, Yibo Xie

Comparison of conventional and advanced radiotherapy techniques for left-sided breast cancer after breast conserving surgery

Medical dosimetry(2020)10.1016/j.meddos.2020.05.004

N/A

0DataRank · unranked

32 citations

Daniel J. Bourgeois, Beibei Guo, Rui Zhang, Yibo Xie

Cost-Effectiveness Analysis of Advanced Radiotherapy Techniques for Post-Mastectomy Breast Cancer Patients

Research Square(2020)10.21203/rs.2.23226/v3

N/A

0DataRank · unranked

0 citations

Beibei Guo, Rui Zhang, Yibo Xie

Cost-Effectiveness Analysis of Advanced Radiotherapy Techniques for Post-Mastectomy Breast Cancer Patients

Research Square(2020)10.21203/rs.2.23226/v2

N/A

0DataRank · unranked

0 citations

Beibei Guo, Rui Zhang, Yibo Xie

BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint

Statistics in Medicine(2021)10.1002/sim.9265

N/A

0DataRank · unranked

9 citations

Yong Zang, Beibei Guo

Cost-effectiveness analysis of radiotherapy techniques for whole breast irradiation

PLoS ONE(2021)10.1371/journal.pone.0248220

N/A

0DataRank · unranked

8 citations

Beibei Guo, Rui Zhang, Yibo Xie

A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy

Statistical Methods in Medical Research(2022)10.1177/09622802221080753

N/A

0DataRank · unranked

12 citations

Yong Zang, Beibei Guo

SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials

Pharmaceutical Statistics(2022)10.1002/pst.2209

N/A

0DataRank · unranked

8 citations

Beibei Guo, Sha Cao, Chi Zhang, Yong Zang, Yifei Zhang

A Bayesian phase I/II design to determine subgroup‐specific optimal dose for immunotherapy sequentially combined with radiotherapy

Pharmaceutical Statistics(2022)10.1002/pst.2265

N/A

0DataRank · unranked

6 citations

Yong Zang, Li‐Hsiang Lin, Rui Zhang, Beibei Guo

Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect

Statistical Methods in Medical Research(2023)10.1177/09622802231158738

N/A

0DataRank · unranked

4 citations

Beibei Guo, Hao Liu, Qian Li, Yong Zang, Mu Shan

Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy

Biometrical Journal(2023)10.1002/bimj.202200246

N/A

0DataRank · unranked

2 citations

Yan Han, Rui Zhang, Beibei Guo, Li‐Hsiang Lin

Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies

Clinical Trials(2024)10.1177/17407745231220661

N/A

0DataRank · unranked

16 citations

Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu +1 more